RA Capital is one of the few mainstream biotech VCs wading into the psychedelics space. The VC firm has invested in three psychedelics startups since 2021. It's looking for companies with short ...

RA Capital Management has raised another $461 million to invest in private biotechs. The closing of the fund comes 15 months after RA Capital set up an inaugural venture fund that has already ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Life science-focused venture capital firms Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners (OUP) have partnered to ...

In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five ...

Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA ...

RA Capital released its latest quarterly 13F fund update with the SEC last week, showcasing new positions in the multi-stage healthcare and life science-focused fund. The Boston-based fund has ...

Following the transaction, RA Capital Healthcare Fund LP directly holds 5,456,521 shares of Mineralys Therapeutics. RA Capital Nexus Fund III, L.P. directly holds 1,867,229 shares. The company ...

A firm that invests in healthcare and life sciences has raised more than a quarter of $1 billion for a new venture fund. Boston-based RA Capital Management said Monday that it had closed its ...

Launching a new product is challenging, but doing it in a space dominated by tech giants requires bold innovation, sharp strategy, and the ability to scale quickly. TechCrunch Disrupt 2024 — taking ...

RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P. and related parties, including Peter Kolchinsky and Rajeev M. Shah, sold 116,046 shares of Vor Biopharma Inc. NASDAQ:VOR common stock ...